Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Positron emission tomography radiochemistry.

N Scott Mason1, Chester A Mathis

  • 1Positron Emission Tomography Facility, Department of Radiology, University of Pittsburgh, B-938, UPMC Presbyterian, 200 Lothrop Street, Pittsburgh, PA 15213-2582, USA. masonns@msx.upmc.edu

Neuroimaging Clinics of North America
|March 18, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoradiography and preclinical PET studies with radiolabeled asyn-44 and ACI-12589 for imaging α-synuclein.

Journal of Parkinson's disease·2026
Same author

Discovery of <i>N</i>-(6-Methoxypyridin-3-yl)quinoline-2-amine Derivatives for Imaging Aggregated α-Synuclein in Parkinson's Disease with Positron Emission Tomography.

Cells·2025
Same author

First-in-human PET neuroimaging of [<sup>18</sup>F]OXD-2314.

European journal of nuclear medicine and molecular imaging·2025
Same author

An inverse association of cerebral amyloid-β deposition and serum docosahexaenoic acid levels in cognitively normal older adults in Japan.

Journal of Alzheimer's disease : JAD·2025
Same author

The development of a PET radiotracer for imaging alpha synuclein aggregates in Parkinson's disease.

RSC medicinal chemistry·2025
Same author

Structure-Activity Relationships and Evaluation of 2-(Heteroaryl-cycloalkyl)-1<i>H</i>-indoles as Tauopathy Positron Emission Tomography Radiotracers.

Journal of medicinal chemistry·2025
Same journal

Understanding Acute Encephalopathy.

Neuroimaging clinics of North America·2026
Same journal

Imaging of Acute Encephalopathies.

Neuroimaging clinics of North America·2026
Same journal

Pediatric Encephalopathy: Inflammatory and Autoimmune Etiologies.

Neuroimaging clinics of North America·2026
Same journal

Pediatric Encephalopathy: Inherited Metabolic Disorders.

Neuroimaging clinics of North America·2026
Same journal

Post-Treatment Causes of Encephalopathy.

Neuroimaging clinics of North America·2026
Same journal

Acute Toxic Leukoencephalopathy: Opioid and other Illicit or Abused Drugs and Environmental Toxins.

Neuroimaging clinics of North America·2026
See all related articles

Designing radiopharmaceuticals for Positron Emission Tomography (PET) imaging faces challenges like short isotope half-lives. Despite this, significant advancements have enabled diverse PET radiotracer applications in humans.

Area of Science:

  • Radiochemistry
  • Nuclear Medicine
  • Medical Imaging

Background:

  • Radiopharmaceutical development for Positron Emission Tomography (PET) imaging is constrained by short isotope half-lives (e.g., Carbon-11, Fluorine-18).
  • High radiation fields from multi-Curie quantities of PET radionuclides and stringent yield/specific activity requirements pose significant challenges.
  • Despite these limitations, substantial progress has been achieved in PET radiotracer development over the past two decades.

Purpose of the Study:

  • To review key advancements and challenges in radiochemistry for PET radiotracer design.
  • To highlight specific areas of radiochemistry focused on PET radiotracers.
  • To underscore the ongoing need for novel PET radiotracers for emerging noninvasive imaging applications.

Main Methods:

Related Experiment Videos

  • Review of recent progress in radiochemistry for PET radiotracer synthesis.
  • Focus on overcoming constraints such as short half-lives and radiation fields.
  • Discussion of established and emerging PET radiotracer applications.

Main Results:

  • Considerable progress has been made in developing and applying various PET radiotracers for human imaging studies.
  • Hundreds of PET radiotracers have been synthesized, demonstrating the field's productivity.
  • Specific areas of radiochemistry contributing to PET radiotracer development are highlighted.

Conclusions:

  • Despite inherent challenges, radiochemistry has successfully advanced PET radiotracer development.
  • The field has enabled a range of PET imaging studies in human subjects.
  • Further research is crucial to develop specific and effective PET radiotracers for new noninvasive imaging applications.